C. Winkelmann

发表

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104

T. Gauler, T. Greten, V. Heinemann, 2015, Acta oncologica.

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine: Interim toxicity analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

T. Gauler, V. Heinemann, S. Boeck, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

D. Niederwieser, M. Herold, A. Franke, 2006, Journal of Cancer Research and Clinical Oncology.

Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens

D. Niederwieser, M. Herold, R. Krahl, 2001, Bone Marrow Transplantation.

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

T. Gauler, T. Greten, V. Heinemann, 2014, BMC Cancer.

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

U. Mansmann, T. Gauler, T. Greten, 2012, British Journal of Cancer.

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Y. Ko, T. Gauler, T. Greten, 2012, Gut.

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone

D. Niederwieser, T. Lindner, W. Pönisch, 2012, Journal of Cancer Research and Clinical Oncology.

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’

T. Gauler, T. Greten, V. Heinemann, 2010, Anti-cancer drugs.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

G. Behre, D. Niederwieser, T. Lindner, 2014, Journal of Cancer Research and Clinical Oncology.

Successful Treatment with Bortezomib in Combination with Bendamustine and Prednisone of Patients with Newly Diagnosed/Untreated Multiple Myeloma and Light Chain Induced Renal Failure

D. Niederwieser, T. Lindner, W. Pönisch, 2011 .

Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)

J. Beck, D. Niederwieser, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Y. Ko, T. Gauler, T. Greten, 2012, Gut.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.